VSTM Q3 2022 Earnings — Verastem, Inc. Revenue & Financial Results | Market Cap Arena

VSTMVerastem, Inc.

$388M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$18M

Net Income

-$18M

EPS (Diluted)

$-1.10

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$15M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$111M

Total Liabilities

$48M

Stockholders' Equity

$63M

Cash & Equivalents

$78M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$2,000	-100.0%
Gross Profit	$0	$2,000	-100.0%
Operating Income	-$18M	-$15M	-19.3%
Net Income	-$18M	-$23M	+20.6%

Revenue Segments

Sale of COPIKTRA license and related assets

$3M100%